331741-94-7 Usage
Description
2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid is a complex organic compound with a unique molecular structure. It is characterized by its ability to act as a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist, which makes it a promising candidate for various applications in the pharmaceutical and medical industries.
Uses
Used in Pharmaceutical Industry:
2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid is used as a PPAR α/γ dual agonist for its potential role in the treatment of various metabolic disorders and conditions. As a dual agonist, it can modulate the activity of both PPARα and PPARγ receptors, which are involved in the regulation of lipid metabolism, glucose homeostasis, and insulin sensitivity.
Used in Metabolic Disorder Treatment:
2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-y l)ethoxy]phenyl]methyl]amino]acetic acid is used as a therapeutic agent for the treatment of metabolic disorders such as diabetes, obesity, and dyslipidemia. By acting as a PPAR α/γ dual agonist, it can help improve insulin sensitivity, reduce plasma glucose levels, and lower triglyceride and cholesterol levels, thereby providing a potential treatment option for patients with these conditions.
Used in Inflammation and Immune Response Modulation:
2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid can also be used as an anti-inflammatory agent. It has been shown to inhibit the production of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and inducible nitric oxide synthase (iNOS) in a concentration-dependent manner. This suggests that it may have potential applications in the treatment of inflammatory diseases and conditions where modulation of the immune response is necessary.
Used in Drug Delivery Systems:
Similar to gallotannin, this compound may also benefit from the development of novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. Utilizing carriers such as organic and metallic nanoparticles could improve the efficacy of 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid in treating the aforementioned conditions.
in vitro
in murine j774 macrophages, muraglitazar dose-dependently reduced lipopolysaccharide-induced inducible nitric oxide synthase (inos) expression, nitrous oxide, il-6 and tnfα production and showed no effect on cell viability at the given concentration. muraglitazar decreased the levels of inos mrna expression, suggesting that the suppressive effect of muraglitazar was mediated at the level of inos transcription. in human hek293 cells, muraglitazar did not affect the nuclear levels of nf- κb p65 compared to the control and did not modulate nf-κb-mediated transcription [1].
in vivo
male charles river mice were administrated orally with muraglitazar at a dose of 12.5, 25, 50 mg/kg for six hours. muraglitazar, in a dose-dependent fashion, prevented the development of oedema. in addition, muraglitazar dose-dependently attenuated inflammation and decreased the levels of il-6, tnfα and inos mrna [1].
IC 50
0.42 μm: shows agonistic activity at peroxisome proliferator-activated receptor α (pparα)
references
[1]. paukkeri, e., leppnen, t., lindholm, m., yam, m., asmawi, m., & kolmonen, a. et al. anti-inflammatory properties of a dual ppargamma/alpha agonist muraglitazar in in vitro and in vivo models. arthritis research & therapy. 2013;15(2): r51.
Check Digit Verification of cas no
The CAS Registry Mumber 331741-94-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,1,7,4 and 1 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 331741-94:
(8*3)+(7*3)+(6*1)+(5*7)+(4*4)+(3*1)+(2*9)+(1*4)=127
127 % 10 = 7
So 331741-94-7 is a valid CAS Registry Number.
InChI:InChI=1/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
331741-94-7Relevant articles and documents
Identification of by-products in support of process development of Muraglitazar
Pathirana, Charles,Rusowicz, Andrew,Suda, Russell,Swaminathan, Shankar,Palaniswamy, Venkatapuram
, p. 283 - 288 (2017/03/16)
-
PROCESS OF PREPARING SUBSTITUTED CARBAMATES AND INTERMEDIATES THEREOF
-
Page/Page column 16-18, (2008/06/13)
An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.
